Invest in Neurocarrus

New first-in-class sensory neuron specific pain drug treats pain without risk of addiction

reserved of a $55,000 goal

INVEST

min $100

INVESTMENT TERMS

$11.25M valuation cap Future Equity

neurocarrus.com

Monterey CA

Technology Healthcare

Drug candidate N-001 provides relief from severe pain in animals caused by inflammation or surgery.

N-001 cannot enter the brain and therefore cannot cause addiction.

N-001 provides pain relief equal to prescription drugs without side effects on muscles or balance.

N-001 is a targeted drug with a unique manufacturing process to discourage competitors.

There is a massive market for the treatment of severe pain both in the U.S. and abroad.

Neurocarrus has a strong track record of non-dilutive funding from federal and state government.

Founder has been working in the space for 25+ years trouble shooting commercial biologicals.

Patents issued on exclusively licensed technology in both the U.S. and select countries.